Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Director Sells $32,130.00 in Stock

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Get Free Report) Director Stephen Ray Mitchell sold 7,000 shares of Vanda Pharmaceuticals stock in a transaction that occurred on Friday, June 13th. The shares were sold at an average price of $4.59, for a total value of $32,130.00. Following the transaction, the director now directly owns 97,082 shares in the company, valued at approximately $445,606.38. The trade was a 6.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Vanda Pharmaceuticals Stock Up 1.6%

Shares of NASDAQ:VNDA opened at $4.58 on Tuesday. The stock has a market cap of $269.92 million, a price-to-earnings ratio of -14.31 and a beta of 0.66. Vanda Pharmaceuticals Inc. has a 12-month low of $3.81 and a 12-month high of $6.63. The business's 50 day moving average is $4.32 and its 200 day moving average is $4.54.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.05. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. The business had revenue of $50.04 million for the quarter, compared to analysts' expectations of $45.13 million. As a group, equities research analysts expect that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of VNDA. Millennium Management LLC boosted its position in Vanda Pharmaceuticals by 220.0% in the first quarter. Millennium Management LLC now owns 2,139,591 shares of the biopharmaceutical company's stock worth $9,821,000 after purchasing an additional 1,470,898 shares during the last quarter. Nuveen LLC purchased a new position in Vanda Pharmaceuticals in the first quarter worth $2,022,000. Schonfeld Strategic Advisors LLC purchased a new position in Vanda Pharmaceuticals in the fourth quarter worth $1,296,000. Susquehanna Fundamental Investments LLC purchased a new position in Vanda Pharmaceuticals in the fourth quarter worth $1,221,000. Finally, Dimensional Fund Advisors LP boosted its position in Vanda Pharmaceuticals by 10.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,488,519 shares of the biopharmaceutical company's stock worth $11,920,000 after purchasing an additional 227,428 shares during the last quarter. Hedge funds and other institutional investors own 88.14% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on VNDA. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $13.00 target price on shares of Vanda Pharmaceuticals in a research report on Wednesday, May 14th. Wall Street Zen raised Vanda Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday. Finally, HC Wainwright reaffirmed a "buy" rating and set a $20.00 target price on shares of Vanda Pharmaceuticals in a research report on Wednesday, May 7th.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.